Morgan Stanley analysts have elevated Colgate-Palmolive to their highest conviction recommendation in the Household & Personal Care sector for 2026, maintaining an overweight rating. They forecast a recovery in organic sales growth following a below-plan 2025 performance, driven by easier year-over-year comparisons, renewed market share gains in oral care, and expansion across developing markets. The firm’s price target reflects a projected 13% upside from the stock’s closing level, aligning closely with Visible Alpha’s Wall Street average.

After organic growth hit a trough of 0.4% in the October quarter, Morgan Stanley projects a rebound to 3% organic sales expansion in 2026, outpacing key competitors. Analysts also model 6% earnings-per-share growth for the year, while cautioning that the company’s own guidance may err on the conservative side when it unveils fourth-quarter results. Together, these assumptions build a pathway for Colgate-Palmolive to reaccelerate above peer growth rates as the year progresses.

Colgate-Palmolive’s 2025 pullback of roughly 30% from peak levels has enhanced its valuation appeal, particularly for income-focused investors. The company boasts a Dividend King track record with a current yield of 2.65%, supported by robust free cash flow generation and a 53.5% payout ratio. Management recently authorized a $5 billion share repurchase program, further underscoring confidence in the balance sheet and long-term strategy. Despite updated guidance calling for 1–2% organic sales growth and flat margins due to the private-label pet food exit, executives maintain that core brand resilience and disciplined capital allocation will sustain shareholder returns.